title: Living-donor kidney transplantation at Mayo Clinic--Rochester.
abstract: With the established benefits of living-donor kidney transplantation, our primary emphasis at Mayo Clinic, Rochester has been to develop protocols that allow living donation to occur even in the presence of relatively unusual or generally contraindicated situations. This approach has significantly increased the number of patients receiving kidney transplants in the past few years. Our protocols for extended criteria donors and recipients along with the exclusive use of laparoscopic donor nephrectomy have been major contributors to the increase in volume. ABO-incompatible and positive-crossmatch living-donor kidney transplant protocols also have increased the availability of transplants for our patients. Protocol biopsies have aided in the diagnosis of subclinical rejection, polyoma virus and chronic allograft nephropathy. Innovative immunosuppressive protocols such as calcineurin inhibitor-free immunosuppression have decreased rejection and improved both short and long-term renal allograft survival.
authors.affiliation: Department of Surgery, Mayo Foundation and Clinic, Rochester, Minnesota, USA.
authors.forename: Mark D
authors.initials: MD
authors.lastname: Stegall
authors.forename: Timothy S
authors.initials: TS
authors.lastname: Larson
authors.forename: Mikel
authors.initials: M
authors.lastname: Prieto
authors.forename: James
authors.initials: J
authors.lastname: Gloor
authors.forename: Stephen
authors.initials: S
authors.lastname: Textor
authors.forename: Scott
authors.initials: S
authors.lastname: Nyberg
authors.forename: Sylvester
authors.initials: S
authors.lastname: Sterioff
authors.forename: Michael
authors.initials: M
authors.lastname: Ishitani
authors.forename: Matthew
authors.initials: M
authors.lastname: Griffin
authors.forename: Thomas
authors.initials: T
authors.lastname: Schwab
authors.forename: Sandra
authors.initials: S
authors.lastname: Talor
authors.forename: Fernando
authors.initials: F
authors.lastname: Cosio
authors.forename: Yogish
authors.initials: Y
authors.lastname: Kudva
authors.forename: Deborah
authors.initials: D
authors.lastname: Dicke-Henslin
authors.forename: Michelle
authors.initials: M
authors.lastname: Kreps
authors.forename: Lynette
authors.initials: L
authors.lastname: Fix
authors.forename: Cherise
authors.initials: C
authors.lastname: Bauer
authors.forename: Mary
authors.initials: M
authors.lastname: Murphy
authors.forename: Kay
authors.initials: K
authors.lastname: Kosberg
authors.forename: Deborah
authors.initials: D
authors.lastname: Tarara
authors.forename: Jorge
authors.initials: J
authors.lastname: Velosa
mesh_terms: D000017:ABO Blood-Group System; D001787:Blood Group Incompatibility; D002102:Cadaver; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival / Q000502:physiology*; D006650:Histocompatibility Testing; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000706:statistics & numerical data*; D010535:Laparoscopy / Q000379:methods; D019520:Living Donors / Q000706:statistics & numerical data; D008910:Minnesota; D009392:Nephrectomy / Q000379:methods; D018579:Patient Selection; D014019:Tissue Donors; D020858:Tissue and Organ Harvesting / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000017:ABO Blood-Group System